

been taken to avoid the introduction of new subject matter into the application as a result of the foregoing modifications.

During the telephone conference, the Examiners suggested amending the claims with the "orally administering an effective dose . . ." language incorporated into claim 11 above. Additionally, Applicant has amended the claims to recite a multivitamin instead of a medicament to comport with the data submitted showing the synergy of the present inventive method. Support for the term multivitamin can be found on page 14, line 23 of the specification and in the Declaration of Larry H. Hollier, M.D., which supports the use of the term multivitamin as a term well known in the art, as well as the most common form of vitamin supplement. Furthermore, Applicant has previously submitted labels from Centrum® and One-A-Day® brand multivitamins which buttresses the use of multivitamin as a term well known to the art.

The Applicant has amended the claims to precise dose ranges, dose ranges based upon the United States Recommended Daily Allowances, or effective doses which are known in the art, and further supported by the articles cited in the specification.

During the telephone conference, the Examiners requested more information regarding the results of the University of California study which support the unanticipatedly beneficial results of the present inventive method. Accordingly, Applicant includes herewith the published article which highlights the study undertaken by Annlia Paganini-Hill et al. The study focused on the relationship between aspirin use and chronic diseases. Among the results of the study was the

finding that the daily use of aspirin increased the risk of ischemic heart disease.

Dr. Kreamer contacted Dr. Paganini-Hill and inquired as to whether her study monitored vitamin usage of the test subjects. Dr. Paganini-Hill responded in the affirmative and provided Dr. Kreamer with the attached Table, which has been previously submitted. Applicant also provides herewith a graphical representation of the data to better illustrate the unanticipated beneficial effects of the present invention. From the attached data it can be seen that the anticipated result of combining aspirin with vitamins would be an increase in the risk of all deaths, total cardiovascular deaths, and ischemic heart disease. Surprisingly, however, the administration of vitamins along with aspirin actually reduces the risk of death from all of these conditions.

Furthermore, Dr. Paganini-Hill's article, while not specifically drawn to the study of aspirin, multivitamins, and heart disease, explains the statistical significance of the data provided herewith and utilized by Dr. Kreamer to support the unanticipated beneficial aspects of his inventive method. As can be seen by Dr. Paganini-Hill's article, the data in the attached table and graph not only shows unanticipatedly beneficial results, but results which are statistically significant within confidences levels accepted in the industry. Accordingly, Applicant respectfully submits that not only is the claimed method not harmful, as would be anticipated from the submitted data on vitamin usage alone and aspirin usage alone, but the claimed method is actually unanticipatedly beneficial and therefore non-obvious.

Based on the foregoing, Applicant respectfully submits that his claims 11-27 are in condition for allowance at this time, patentably distinguishing over the cited prior art. Accordingly, reconsideration of the application and passage to allowance are respectfully solicited.

The Examiner is respectfully urged to call the undersigned attorney at (515) 288-2500 to discuss the claims in an effort to reach a mutual agreement with respect to claim limitations in the present application which will be effective to define the patentable subject matter if the present claims are not deemed to be adequate for this purpose.


Respectfully submitted,

Date: October 13, 1994

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

October 13, 1994

By Brett J. Trout



Kent A. Herink
Registration No. 31,025
Brian J. Laurenzo
Registration No. 34,207
Brett J. Trout
Registration No. 37,250
DAVIS, HOCKENBERG, WINE,
BROWN, KOEHN & SHORS, P.C.
666 Walnut St., Suite 2500
Des Moines, Iowa 50309
Telephone: (515) 288-2500

ATTORNEYS FOR APPLICANT

PAPERS

Aspirin use and chronic diseases: a cohort study of the elderly

Annlia Paganini-Hill, Ann Chao, Ronald K Ross, Brian E Henderson

Abstract

Objective—To evaluate the associations between the use of aspirin and the incidences of cardiovascular diseases, cancers, and other chronic diseases.

Design—Postal questionnaire survey to elicit details of aspirin use.

Setting—Californian retirement community.

Subjects—All 22 781 residents of the community (white, affluent, and well educated) were sent a questionnaire that included questions on medical history and the use of drugs such as analgesics, laxatives, and vitamin supplements. In all 61% responded (13 987; 8881 women and 5106 men; median age 73). They formed the cohort that was followed up for 6½ years using discharge summaries from three hospitals serving the area and death certificates from the health department. Only 13 respondents were lost to follow up but seemed not to have died.

Main outcome measures—Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily.

Results—Age adjusted incidences were computed with an internal standard and five age groups. By 1 January 1988 there had been 25 incident cases of kidney cancer among all participants; 341 incident cases of stroke, 253 of acute myocardial infarction, 220 of ischaemic heart disease, and 317 of other heart disease were reported among respondents without a reported history of angina, myocardial infarction, or stroke. The incidence of kidney cancer was raised among those who took aspirin daily compared with those who did not take it, although the increase was significant only in men (relative risks=6·3, 95% confidence interval 2·2 to 17, for men and 2·1, 0·53 to 8·5, for women). Those who took aspirin daily showed no increased risk of any other cancer, except colon cancer for both sexes combined (relative risk=1·5, 1·1 to 2·2). The risk of acute myocardial infarction was reduced slightly among regular users of aspirin in men but not women. The risk of ischaemic heart disease was almost doubled in those who took aspirin daily compared with non-users (relative risks=1·9, 1·1 to 3·1, for men and 1·7, 1·1 to 2·7, for women). Small, non-significant increased risks of stroke were observed in both sexes.

Conclusion—The daily use of aspirin increased the risk of kidney cancer and ischaemic heart disease.

Introduction

In the United States vascular diseases account for about 1·2 million deaths, or half of all deaths each year. Recently, the results of a large clinical trial showing that regular use of aspirin may prevent myocardial

infarction have received widespread publicity.¹ Given the preliminary nature of this published report, the limitation of the study to men, some evidence of internal inconsistency of the results, and the contradictory findings of other trials,² this relation cannot yet be considered secure.

As part of a prospective study on lifestyle practices and disease prevention in a retirement community in southern California, we assessed the association between regular use of analgesics containing aspirin and the incidence of several chronic diseases, including cardiovascular diseases and cancer.

Methods

In June 1981 a detailed health questionnaire was sent to all residents of Leisure World, Laguna Hills, a retirement community near Los Angeles, California. New residents who moved into the community after this date were sent the questionnaire in June 1982, June 1983, and October 1985. Residents of this community are almost always white, moderately affluent, and well educated, and about two thirds are women.

The health questionnaire requested information on previous medical diagnoses, including angina, acute myocardial infarction, hypertension, rheumatoid arthritis, and diabetes; height and weight; the use of drugs, including analgesics, laxatives, and vitamin supplements; the use of cigarettes and alcohol; exercise habits; dietary intake of certain foods; and for women menstrual and reproductive events, including use of oestrogen replacement treatment. The use of analgesics was ascertained from the questions: "Which of the following best describes your use of non-prescription pain medication? Several times a day; daily; weekly; monthly; less often or never" and "When you take non-prescription pain medication, what is the brand (for example, Empirin, Anacin, Bayer Aspirin) you usually take?"

The cohort was followed up for all hospital admissions to three hospitals serving the area (85% of these occur at one hospital immediately adjacent to the community) and for deaths with the death certificate records of the local health department. Death certificates were also obtained for those who had died and been identified by the community business office, from the obituary column of the local newspaper, and from information provided by relatives and friends. In addition, we conducted two postings of follow up questionnaires to the cohort in 1983 and 1985. To date only 13 members of the cohort have been lost to follow up; search of the National Death Index (a computerised register of death record information maintained by the National Center for Health Statistics) did not show that these people had died.

The members of the cohort were followed up to the time of the event of interest (admission to hospital) or death or to 1 January 1988, whichever came first. Age

Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033-0800, United States

Annlia Paganini-Hill, PhD, professor

Ann Chao, MS, statistical analyst

Ronald K Ross, MD, professor
Brian E Henderson, MD, professor

Correspondence to:
Dr Paganini-Hill.

Br Med J 1989;299:1247-50

adjusted relative risks using five age groups (<75, 75-79, 80-84, 85-89, ≥90) and p values were obtained with a regression method that assumed that the development of cancer or chronic disease could be regarded as a Poisson process with a constant hazard rate for a given person.²³ The generalised linear interactive modelling (GLIM) software package program was used to make these calculations.⁴ All reported p values are two sided.

Results

The residents' median age was 73. After three postings 13 987 residents (61% of the 22 781 residents) returned questionnaires; 8881 of the respondents were women. The distribution of sex was comparable in respondents and non-respondents, but the non-respondents were slightly older; overall mortality was greater in non-respondents in the first few years of follow up and then became identical with that in the respondents.

By 1 January 1988 the 8881 women and 5106 men in the cohort had contributed over 42 000 and 25 000 person years of follow up, respectively. The incidence of kidney cancer was increased among daily users of aspirin in both men and women, although the result was significant only in the men (table I). This increase was more evident for renal cell carcinomas (sex and age adjusted relative risk=6·3, 95% confidence interval 2·0 to 20, p<0·01, for daily aspirin users compared with non-users) than for transitional cell cancers (relative risk=2·2, 0·65 to 7·6, p=0·20).

Colon cancer showed some increased risk with the use of aspirin in both sexes (table I). The result was significant in both sexes combined (sex and age adjusted relative risk=1·5, 1·1 to 2·2, p<0·05 for daily aspirin users compared with non-users). The increased risk was not restricted to a particular segment of the colon (data not shown). No other strong or significant cancer associations were apparent between the regular use of aspirin and the development of any other cancer.

TABLE I—Numbers of cases and age adjusted relative risks for incidence of cancer by sex and use of analgesics containing aspirin

	Colon	Lung	Bladder	Kidney	Prostate or breast			
Aspirin use	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk
Men:								
None (n=3490)	47	1·00	46	1·00	55	1·00	6	1·00
<Daily (n=685)	13	1·39	8	0·87	4	0·37	18	0·90
Daily (n=876)	19	1·67	15	1·35	15	1·12	9	6·28*
Women:								
None (n=6021)	66	1·00	32	1·00	14	1·00	6	1·00
<Daily (n=1417)	15	0·95	8	1·00	5	1·56	1	0·72
Daily (n=1380)	21	1·41	2	0·29	3	0·89	3	2·11

*p<0·05.

TABLE II—Numbers of cases and age adjusted relative risks for incidence of cardiovascular diseases (excluding people with reported history of angina, acute myocardial infarction, and stroke) by sex and use of analgesics containing aspirin

	Total (ICD 390-438)	Stroke (ICD 430, 431, 434, 436)	Acute myocardial infarction (ICD 410)	Ischaemic heart disease (ICD 411-414)	Other heart disease (ICD 420, 424, 425, 428, 429, 440, 441)			
Aspirin use	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk
Men:								
None (n=2587)	406	1·00	101	1·00	98	1·00	54	1·00
<Daily (n=529)	80	1·02	16	0·87	13	0·64	17	1·51
Daily (n=516)	113	1·46*	26	1·22	14	0·73	19	1·64
Women:								
None (n=5169)	568	1·00	135	1·00	86	1·00	77	1·00
<Daily (n=1207)	122	0·97	26	0·88	22	1·16	23	0·85
Daily (n=1063)	166	1·39*	37	1·27	20	1·06	28	1·72*

For analyses of the relation between cardiovascular disease and use of aspirin we excluded 1432 men and 1394 women who had reported a history of angina, myocardial infarction, or stroke in the initial survey (table II). The incidence of ischaemic heart disease was raised among daily users of aspirin compared with non-users among both men and women (relative risk=1·9, 1·1 to 3·1, p<0·05 and 1·7, 1·1 to 2·7, p<0·05, respectively). Except for "other heart disease" (including various diseases, the numerically most important of which was heart failure) in men, the use of aspirin was not significantly related to any other vascular disease examined. A 20-30% increased risk of stroke was, however, seen in men and women who took aspirin daily, but neither of these results was significant (sex and age adjusted relative risk=1·3, 0·96 to 1·7, p=0·16 for daily aspirin users compared with non-users). For all cardiovascular disease combined the risk was raised among daily users of aspirin compared with non-users among both men and women (relative risks=1·5, 1·2 to 1·8, p<0·05 and 1·4, 1·2 to 1·7, p<0·05, respectively).

Other chronic diseases examined because of previous evidence of a possible association with regular use of aspirin included gastrointestinal bleeding, gastric ulcers, and cataracts (table III). Among women, those who used aspirin less than daily showed a significant reduction in risk for ulcers (relative risk=0·3, 0·14 to 0·74, p<0·05), but there was no evidence of a dose-response effect. No other result was significant or substantially different from unity.

TABLE III—Numbers of cases and age adjusted relative risks for incidence of other diseases by sex and use of analgesics containing aspirin

Aspirin use	Gastrointestinal bleeding		Ulcers		Cataracts	
	No of cases	Relative risk	No of cases	Relative risk	No of cases	Relative risk
Men:						
None (n=3490)	37	1·00	53	1·00	130	1·00
<Daily (n=685)	21	0·73	13	1·26*	21	0·83
Daily (n=876)	13	1·38	13	1·00	39	1·21
Women:						
None (n=6021)	37	1·00	81	1·00	343	1·00
<Daily (n=1417)	8	0·95	6	0·32	63	0·80
Daily (n=1380)	12	1·29	5	0·76	99	1·21

Discussion

Five case-control studies of cancer of the renal pelvis^{5,9} and two of renal cell carcinoma¹⁰ have evaluated the association with use of analgesics, and we have reviewed the subject.¹¹ Two studies conducted by McCredie *et al* in New South Wales suggested a strong association between "regular" use of analgesics and cancer of the renal pelvis in both sexes.¹² The second study suggested that in women this strong association was limited mainly to compounds containing phenacetin.¹³ In a study in Minnesota McLaughlin *et al* found 3·9-fold and 3·7-fold excess risks of cancer of the renal pelvis in men and women, respectively, who were regular long term (>36 months) users of drugs containing phenacetin or paracetamol compared with non-users.¹⁴ Neither result, however, was significant. Our case-control study of cancer of the renal pelvis and ureter suggested that heavy use of analgesics obtained over the counter without a prescription is associated with an increased risk and that the increased risk extends across formulations containing all the main active ingredients of preparations currently used in the United States, including aspirin.⁹ The data on renal cell carcinoma are scanty and inconclusive.^{5,10} Our current results are compatible with these published

cluded 1432 men at a history of angina in the initial survey; heart disease was compared with no history (relative risk=1·1 to 2·7, $p<0·01$) or "other disease" (including most important use of aspirin with vascular disease). Risk of stroke was 1·1 who took aspirin was significant ($p=0·96$ to 1·7, $p=0·1$ with non-users). The risk was raised with non-users' risks=1·5, 1·2, 1·05, respectively, and because of protection with regular intestinal bleeding. Among women daily showed users (relative risk=1·1) there was no evidence result was significant.

stated relative risks for analgesics containing

regular use of aspirin and the development of renal cell carcinoma.

are not aware of previous reports of an association between cancer of the colon and aspirin intake. Aspirin causes gastric irritation. In sufficiently high doses and combined with interference in absorption by foodstuffs in the intestinal lumen or through other mechanisms, aspirin might similarly affect the large bowel. Such irritation may lead to increased activity of mucosal stem cells and to an increased risk of cancer.

Evidence that regular administration of aspirin may be beneficial to patients with established coronary heart disease comes from several sources¹²⁻¹⁵ and has been recently reviewed by the Antiplatelet Trialists' Collaboration.¹⁶ Overall, in 25 completed randomised trials of antiplatelet treatment (including aspirin) in patients with a history of transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction allocation to antiplatelet treatment reduced mortality from vascular diseases by 15% but had no apparent effect on mortality from non-vascular diseases. There was no significant difference among the effects of the different types of antiplatelet treatment tested (300-325 mg aspirin daily, higher aspirin doses, sulphinpyrazone, or high dose aspirin with dipyridamole) or between the effects in patients with histories of cerebral or cardiac vascular diseases.

There have been two randomised trials of aspirin for the primary prevention of cardiovascular disease. The physicians' health study is a double-blind, placebo-controlled trial of 22 071 male doctors in the United States between the ages of 40 and 84. A primary aim of the study is to determine whether 325 mg aspirin taken every other day reduces mortality from and incidence of vascular disease.¹⁷ After an average of 4·8 years of follow up there was no difference between the aspirin and placebo groups in total cardiovascular deaths (relative risk=0·99). The overall mortality from cardiovascular disease was extraordinarily and inexplicably low: 733 deaths expected v 88 observed. The patterns of risk of vascular disease associated with the regular use of aspirin in that study are strikingly similar to the patterns of incidence in men in our study. The physicians' health study observed a 47% reduction in the overall risk of fatal and non-fatal myocardial infarction (relative risk=0·53, $p<0·00001$). We observed a non-significant reduction in risk of myocardial infarction of 36% and 27% among those who took aspirin daily and those who took it less often, respectively. For stroke there was a non-significant increase of 15% among those receiving aspirin in the physicians' health study (relative risk=1·15, $p=0·41$); our results indicate a 22% increase in risk associated with daily aspirin use. For deaths from ischaemic heart disease (data on morbidity were not reported) the relative risk was increased only slightly in the physicians' health study (relative risk=1·08, $p=0·81$) compared with a substantially higher and significant increase observed in our study (relative risk=1·86). We presume, however, that the category "sudden death" in the physicians' health study (relative risk=1·49) includes subjects with underlying ischaemic heart disease. The relative risk for "other" cardiovascular disease deaths (relative risk=1·79) was also quite similar to that in our study (relative risk=1·64).

The only other data on the role of aspirin in the primary prevention of cardiovascular disease derive from a randomised trial of 5139 British doctors that tested 500 mg of aspirin daily.¹⁸ In contrast with the physicians' health study the British data showed no differences in risk of fatal or non-fatal myocardial infarction between those assigned to the aspirin and the control groups. Like the physicians' health study and our study, a slight but non-significant excess of strokes

group. No difference was observed in the mortality from all cardiovascular diseases.

Although aspirin treatment has proved benefit for those with a history of cardiovascular disease (secondary prevention), data from the two clinical trials combined with the results from our large prospective study suggest that the risk-benefit equation might balance differently for primary prevention. Though the reduction in mortality from acute myocardial infarction in the physicians' health study was significant, it was accompanied by small increases in mortality from other vascular diseases so that no overall reduction in mortality from vascular diseases was apparent. This observation is supported by data on mortality from the British study and from our data on the incidences of chronic disease. We extend these observations to show no reduction in incidence of vascular disease in women who use aspirin daily. In fact, our study found a significantly increased incidence of ischaemic heart disease in regular aspirin users of both sexes and an increased incidence of "other" heart disease, which was significant in men.

Gastrointestinal discomfort and bleeding and gastric ulcers are established hazards of aspirin use, especially in high doses.^{16,19-22} In a resurvey of a sample of our cohort who took analgesics daily we found that a quarter of the 190 respondents avoided analgesics containing aspirin because of a history of ulcers or stomach problems. If such people at high risk avoid taking aspirin the risk of ulcers in aspirin users would be reduced, as observed in our study.

The use of aspirin has been reported to be protective for cataracts in studies of patients with rheumatoid arthritis,²³ diabetic patients,²⁴ and patients admitted for cataract extraction.^{25,26} Other studies have not, however, confirmed this effect,^{11,17-20} and we see no apparent protection in our cohort despite a substantial number of cases.

Although our data on use of analgesics are self reported, we have evidence that these data are reliable.¹⁰ In the resurvey conducted in 1988 of 190 respondents who took analgesics daily 132 (69%) were still taking an analgesic every day. For these 132 the primary reasons for taking an analgesic were reported to be for arthritis (61 (46%)); for prevention of heart disease, angina, and stroke and as a blood thinner (30 (23%)); and for headache (7 (5%)).

This work was supported by grants CA32197 and CA17054 from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland. We thank Mary Arthur and Beverly Ducey, research staff, for their help, and the residents of Leisure World, Laguna Hills, California, whose cooperation made this work possible.

- 1 Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1988;318:262-4.
- 2 Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. *Journal of the American Statistical Association* 1983;78:1-12.
- 3 Frooman EL. The analysis of rates using Poisson regression models. *Biometrics* 1983;39:665.
- 4 Baker RJ, Nelder JA. *The GLIM system: release 3*. Oxford: Numerical Algorithms Group, 1978.
- 5 Armstrong B, Garrod A, Doll R. A retrospective study of renal cancer with special reference to coffee and animal protein consumption. *Br J Cancer* 1976;33:127-36.
- 6 McCredie M, Ford JM, Taylor JS, Stewart JH. Analgesics and cancer of the renal pelvis in New South Wales. *Cancer* 1982;49:2617-25.
- 7 McCredie M, Stewart JH, Ford JM, MacLennan RA. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. *Br J Urol* 1983;55:220-4.
- 8 McLaughlin JK, Blot WJ, Mandel JS, Schuman LM, Mehl ES, Fraumeni Jr. Etiology of cancer of the renal pelvis. *JNCI* 1983;71:287-91.
- 9 Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE. Analgesics, cigarette smoking and other risk factors for cancer of the renal pelvis and ureter. *Cancer Res* 1989;49:1045-9.
- 10 McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni Jr. A population-based case-control study of renal cell carcinoma. *JNCI* 1984;72:275-84.
- 11 Paganini-Hill A, Ross RK, Henderson BE. Epidemiology of renal cancer. In

- Skinner DG, Lieskovsky G, eds. *Diagnosis and management of cancer*. Philadelphia: WB Saunders, 1988:32-9.

12 Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. *Br Med J* 1974;ii:40-3.

13 Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. *Br Med J* 1974;ii:436-40.

14 Coronary Drug Project Research Group. Aspirin in coronary heart disease. *J Chronic Dis* 1978;29:625-42.

15 Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. *JAMA* 1980;243:661-9.

16 Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. *Br Med J* 1988;296:320-31.

17 Young FE, Nightingale, Temple RA. The preliminary report of the finding of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction. *JAMA* 1988;259:3158-60.

18 Peter R, Gray R, Collins R, et al. A randomised trial of the effects of prophylactic daily aspirin among male British doctors. *Br Med J* 1988;296:313-6.

19 Belcon MC, Rooney PJ, Tugwell P. Aspirin and gastrointestinal haemorrhage: a methodologic assessment. *J Chronic Dis* 1985;38:101-11.

20 Piper DW, McIntosh JH, Ariotti DE, Fenton BH, MacLennan R. Analgesic ingestion and chronic peptic ulcer. *Gastroenterology* 1981;80:427-32.

21 McIntosh JH, Byth R, Piper DW. Environmental factor chronic gastric ulcer: a case control study of exposure vari first symptoms. *Gut* 1985;26:789-98.

22 Faulkner G, Prichard P, Somerville K, Langman MJS. Aspirin peptic ulcers in the elderly. *Br Med J* 1988;297:1311-3.

23 Cotlier E. Aspirin and senile cataract in rheumatoid : 1981;ii:338-9.

24 Cotlier E. Senile cataracts: evidence for acceleration by diabe tion by salicylate. *Clin Ophthalmol* 1981;16:113-8.

25 Van Hennigen R, Harding JJ. Do aspirin-like analgesics cataract? *Lancet* 1986;i:1111-3.

26 Cotlier E. Rheumatoid arthritis and cataract surgery. *Int Op* 127-9.

27 Seigel D, Sperduto RD, Ferris FL III. Aspirin and cataracts 1982;89:47-8A.

28 West SK, Munoz BE, Newland HS, Emmett EA, Taylor evidence for aspirin use and prevention of cataracts. *A* 1987;105:1229-31.

29 Kewitz H, Nitze M, Gaus V. Aspirin and cataract. *Lancet* 1986; 30 Paganini-Hill A, Ross RK. Reliability of recall of drug usage related information. *Am J Epidemiol* 1982;116:114-22.

(Accepted 15 September 1989)

Perinatal transmission of HIV-I in Zambia

S K Hira, J Kamanga, G J Bhat, C Mwale, G Tembo, N Luo, P J Perine

Abstract Objective—To determine the occurrence of infected mothers are also infected.¹⁻⁴ We studied vertical transmission of HIV-I from women positive for the virus and the prognosis for their babies.

Design—Women presenting in labour were tested for HIV-1. Their newborn babies were also tested. Women positive for the virus were followed up with their babies for at least 12 months.

Setting—Teaching hospital in Lusaka, Zambia.
Subjects—1954 Women, of whom 227 were seropositive. Of 205 babies, 192 were positive for HIV-I. After birth 109 seropositive mothers and their babies and 40 seronegative mothers and their babies were available for follow up.

Patients and methods

During February to May 1987, 1954 con women delivering at this hospital were entered study. We obtained detailed histories after informed consent and performed a thorough examination and collected 3-5 ml venous blood was taken from live born infants.

Main outcome measures—Serological examination of mothers and their babies by western blotting. Birth weight and subsequent survival of babies. Women and babies were tested over two years for signs of seroconversion and symptoms of infection with HIV, AIDS related complex, and AIDS.

Results—Of the 109 babies born to seropositive mothers and available for follow up, 18 died before 8 months, 14 with clinical AIDS. Of the 91 remaining, 13 were seropositive at 8 months. By 24 months 23 of 36 surviving babies were seropositive, and a further five infected babies had died, four were terminally ill, 7 had AIDS related complex, and two had no symptoms. The overall rate of perinatal transmission was 42 out of 109 (39%). The overall mortality of infected children at 2 years was 19 out of 42 (44%). Before the age of 1 year infected children had pneumonia and recurrent coughs, thereafter symptoms included failure to thrive, recurrent diarrhoea and fever, pneumonia, candidiasis, and lymphadenopathy. All babies had received live attenuated vaccines before 8 months with no adverse effects.

Conclusions—Vertical transmission from infected mothers to their babies is high in Zambia and prognosis is poor for the babies. Perinatal transmission and paediatric AIDS must be reduced, possibly by screening young women and counselling those positive for HIV-I against future pregnancy.

Patients and methods

During February to May 1987, 1954 con women delivering at this hospital were entered into study. We obtained detailed histories after informed consent and performed a thorough physical examination and collected 3-5 ml venous blood was taken from live and stillborn infants. Serum samples of mother, baby, and, in some cases, the father were tested for antibodies to HIV by enzyme linked immunosorbent assay (ELISA) and western blot analysis. We attempted to trace and follow up two groups: (a) all women positive for anti-HIV-I and their infants and (b) 40 sets of negative for antibody to HIV-I and their infants. Seropositive women and their spouses were counseled. Repeat venous blood samples were collected from mothers and infants in both the groups at 6, 8, 12, and 24 months and tested for antibodies to HIV. A complete blood count was done. All children received vaccines: BCG at birth, oral polio and diphtheria-tetanus-pertussis, and tetanus at 3, 4, and 5 months, and measles at 8 months.

Data were analysed by using χ^2 tests with epi-logic software from the Centers for Disease Control.

Results

Of 1954 women screened at delivery, 227 (12%) seropositive for HIV-I. The seropositive women were significantly younger with a mean (SD) age of (5.4) years (Student's *t* test $p < 0.05$). The seronegative women had a mean (SD) age of 25.1 (7.7). Among seropositive women, 62 (27%) were primigravidae and 185 (82%) were married. Risk factors such as higher number of lifetime sexual partners (table I), single or divorced or widowed, in educational state (table II), history of travel abroad, and working (table III) were associated with high seroprevalence of HIV-I. Fifty two (23% of the seropositive women had advanced

